


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+2.70%
+16.27%
-6.18%
+21.12%
REGN
Regeneron Pharma
$646.34
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
Chart
$569.9 (+13.41%)
$561.55 (+15.10%)
$522.68 (+23.66%)
$744.6 (-13.20%)
REGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
REGN Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayNVS
125.66
+0.45%
SNY
49.26
+0.30%
MRK
84.57
+0.88%
AZN
81.54
-0.61%
OPK
1.38
-0.72%
What is REGN current stock price?
What are REGN stock strengths?
What risks are associated with REGN stock?
When is REGN next earnings report?
What is REGN market cap and volume?
What is REGN's current Stock IQ?
Should I buy REGN stock right now?
Is REGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for REGN?
What does a 'Strong Sell' rating mean for REGN?
What factors influence REGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+2.70%
+16.27%
-6.18%
+21.12%
REGN
Regeneron Pharma
Current Price
$646.34
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
Linked to REGN
NVS
125.66
+0.45%
SNY
49.26
+0.30%
MRK
84.57
+0.88%
AZN
81.54
-0.61%
OPK
1.38
-0.72%

Chart
$569.9 (+13.41%)
$561.55 (+15.10%)
$522.68 (+23.66%)
$744.6 (-13.20%)
REGN Analysts Opinion
REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
REGN Street view is extremely bullish and have positive views on the near-term outlook
REGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
REGN Latest Analysis
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Mon Nov 3, 2025
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Fri Oct 31, 2025
Opko Health Inc.s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals. Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc. an Opko Health Inc. (NASDAQ:OPK) company announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest
Fri Oct 31, 2025
Citigroup Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation. Fintel reports that on October 29 2025 Citigroup maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 14.57% Upside
Thu Oct 30, 2025
Wells Fargo Maintains Regeneron Pharmaceuticals (REGN) Equal-Weight Recommendation. Fintel reports that on October 29 2025 Wells Fargo maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 14.57% Upside
Thu Oct 30, 2025
Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation. Fintel reports that on October 29 2025 Guggenheim maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 14.57% Upside
Thu Oct 30, 2025
Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation. Fintel reports that on October 29 2025 Cantor Fitzgerald maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Overweight recommendation. Analyst Price Forecast Suggests 14.57% Upside
Thu Oct 30, 2025
B of A Securities Maintains Regeneron Pharmaceuticals (REGN) Underperform Recommendation. Fintel reports that on October 29 2025 B of A Securities maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Underperform recommendation. Analyst Price Forecast Suggests 14.57% Upside
Thu Oct 30, 2025
Regeneron Pharmaceuticals declares $0.88 dividend.
Wed Oct 29, 2025
Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies . (RTTNews) - Wednesday Regeneron Pharmaceuticals Inc. (REGN) and ModeX Therapeutics Inc. an OPKO Health company (OPK) entered into a license and collaboration agreement to discover and develop multispecific antibodies for several therapeutic indications of mutual interest.
Wed Oct 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
REGN Stock trends
REGN Stock performance
REGN Stock analysis
REGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.